4 completed, 2 unknown, 1 recruiting, 1 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Unknown 2 |
Follow Hepatoma: new trials by email Literature Review of Hepatoma trials Research Report on Hepatoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. MDN-001 Injection(Yttrium-90 Microsphere Injection) - Hepatoma, Unresectable Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Suzhou Mednovo Yi Medical Technology Co., Ltd. | 40 | 2025-08-04 | 2026-02-06 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies CAR-T/TCR-T cells immunotherapy - Esophagus Cancer, Hepatoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 50 | 2019-09-01 | 2021-02-04 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies CAR-T cell immunotherapy - B-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 73 | 2018-03-01 | 2019-12-11 |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma TKM-080301 - Hepatocellular Carcinoma, Hepatoma | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2014-06-01 | 2019-01-16 |
| Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 1 | Withdrawn | Medical College of Wisconsin | 2012-06-01 | 2013-09-05 | |
| Sorafenib and TRC105 in Hepatocellular Cancer TRC 105, Sorafenib - Hepatoma, Liver Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-11 | 2019-01-23 |
| IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread Salmonella typhimurium - Cancer of the Liver, Liver Cancer | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 22 | 2010-04-01 | 2020-07-20 |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost - Hepatocellular Carcinoma, Hepatoma | Phase 1 | Terminated | Lisa H. Butterfield, Ph.D. | 2 | 2009-06-01 | 2015-12-03 |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na - Hepatoma, Advanced Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 16 | 2008-06-01 | 2017-06-23 |
Carcinoma, Hepatocellular (9) · Liver Neoplasms (5) · Esophageal Neoplasms (2) · Glioma (2) · Stomach Neoplasms (2) · Adenoma, Liver Cell (1) · Biliary Tract Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Leukemia, Myeloid (1) · Liver Neoplasms, Experimental (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1)
Adenocarcinoma (9) · Carcinoma (9) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Liver Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Liver Neoplasms (4) · Adenoma (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2)
Sorafenib (2) · Immunotherapy, Adoptive (1) · Irinotecan (1) · ON 01910 (1) · Oxaliplatin (1) · Radiotherapy (1) · TKM-080301 (1) · carotuximab (1)
Shenzhen BinDeBio Ltd. (2) · Arbutus Biopharma Corporation (1) · Lisa H. Butterfield, Ph.D. (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · National Cancer Institute (NCI) (1) · Suzhou Mednovo Yi Medical Technology Co., Ltd. (1) · Traws Pharma, Inc. (1)
United States (6) · China (4) · Canada (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Beth A. Erickson-Wittmann, M.D. (1) · Edward W. Greeno, MD (1) · James Pingpank, MD (1) · Mark Kowalski, M.D., Ph.D. (1) · Takao Ohnuma, M.D. (1) · Tim F Greten, M.D. (1)
R01CA104524 (1)